COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration (CRUF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01138683
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : January 10, 2012
Information provided by (Responsible Party):
University Hospital, Ghent

Brief Summary:
The CRUF trial is a prospective randomized monocentric trial comparing different impact of diuretics versus ultrafiltration on renal congestion, plasma refill rate, echocardiographic filling pressures, neurohormonal activation and biomarkers of Acute Kidney Injury (AKI).

Condition or disease Intervention/treatment Phase
Acute Decompensated Heart Failure Procedure: ultrafiltration Drug: diuretics Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration
Study Start Date : February 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Active Comparator: ultrafiltration group Procedure: ultrafiltration
Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.

Active Comparator: diuretics group Drug: diuretics
Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.

Primary Outcome Measures :
  1. Incidence of AKI and determining factors in patients with acute decompensated heart failure with treated with ultrafiltration versus diuretics [ Time Frame: at 6 months ]

Secondary Outcome Measures :
  1. determination of the value of Neutrophil gelatinase-associated lipocalin (NGAL) to predict AKI in acute decompensated heart failure (vs creatinine, Cystatin C,measured urinary creatinine clearance) in patients treated with diuretics vs ultrafiltration. [ Time Frame: at 48h after treatment start ]
  2. Combined endpoint of mortality/rehospitalisation-urgent outpatient visit due to heart failure [ Time Frame: at 6 months ]
  3. Kidney function measured by creatinine [ Time Frame: after 28 days and 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >18 years old
  • Severe systolic heart failure with ejection fraction <40%
  • And Hospitalisation for decompensated heart failure
  • And New York Heart Association (NYHA) III or IV
  • And 1 of the following:

    • Jugular vein distension>6cm
    • Tissue Doppler mitral annulus lateral>12 or medial>15
    • Chest X-ray: pulmonary edema or pleural effusion

Exclusion Criteria:

  • Need for inotropic or vasopressive agents
  • Use of intravenous (IV) contrast media
  • Acute coronary syndrome
  • Need of dialysis
  • Severe co-morbidity
  • Contra-indications for anticoagulation
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01138683

Layout table for location information
University Hospital Ghent
Ghent, Belgium
Sponsors and Collaborators
University Hospital, Ghent
Layout table for investigator information
Principal Investigator: Sofie Gevaert, MD University Hospital Ghent, Belgium
Additional Information:
Layout table for additonal information
Responsible Party: University Hospital, Ghent Identifier: NCT01138683    
Other Study ID Numbers: 2009/539
2009-017589-22 ( EudraCT Number )
First Posted: June 7, 2010    Key Record Dates
Last Update Posted: January 10, 2012
Last Verified: January 2012
Keywords provided by University Hospital, Ghent:
Acute decompensated heart failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Natriuretic Agents
Physiological Effects of Drugs